Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aptevo Therapeutics Inc (APVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Aptevo Therapeutics' Novel Bispecific Antibody Therapeutic APVO436 Shows Broad Activity in Primary Human AML Samples

New APVO436 Preclinical Data Show Robust T-Cell Engagement and Cytotoxicity in AML Patient Specimens

APVO : 4.18 (+5.03%)
Aptevo Therapeutics Announces Plans to Conduct Phase 2 Study of Otlertuzumab in Peripheral T-Cell Lymphoma

Anticipates 2 IND Filings in 2018 for Novel Bispecific Antibody Candidates

APVO : 4.18 (+5.03%)
Aptevo Therapeutics Reports Third Quarter 2017 Financial Results

Strengthened Cash Position to Support Ongoing R&D and Commercial Activities;

APVO : 4.18 (+5.03%)
Emergent (EBS) Q3 Earnings Beat Estimates, Guidance Raised

Emergent's (EBS) earnings and revenues beat estimates in Q3. Revenues also rise year over year on higher product sales and increase in contract manufacturing revenues.

APVO : 4.18 (+5.03%)
EBS : 46.80 (+1.10%)
GSK : 34.99 (-0.71%)
SNY : 43.17 (+0.19%)
Aptevo Therapeutics Presents New Preclinical Data on APVO436 - a Next Generation ADAPTIR(TM) Bispecific Antibody Candidate

New Preclinical Data Show APVO436 Demonstrates Rapid and Significant Reduction in Skeletal Tumor Burden in Mice with Well-Established and Disseminated Tumors

APVO : 4.18 (+5.03%)
Alligator Bioscience Aptevo Therapeutics: Tumor Antigen 5T4 Associated with Many Forms of Solid Tumors Identified as the Second Target for ALG.APV-527

LUND, Sweden and SEATTLE, Washington, October 24, 2017 /PRNewswire/ --

APVO : 4.18 (+5.03%)
Tumor Antigen 5T4 Associated With Many Forms of Solid Tumors Identified as the Second Target for ALG.APV-527 - a Novel Bispecific Antibody Candidate Being Developed by Alligator Bioscience and Aptevo Therapeutics

ALG.APV-527 Engineered to Engage the Immune System for the Potential Treatment of Multiple Solid Tumor Indications

APVO : 4.18 (+5.03%)
Aptevo Therapeutics Showcases New Mechanism of Action for Its ADAPTIR Platform at the Inflammation Research Society Meeting

New Autoimmune Candidate APVO210 Demonstrates Targeted Cytokine Delivery for Application in Various Autoimmune and Inflammatory Diseases

APVO : 4.18 (+5.03%)
Aptevo Therapeutics, Analyst Coverage, ADAPTIR Platform and Recent Drug Asset Sale

NEW YORK, NY / ACCESSWIRE / October 10, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive...

APVO : 4.18 (+5.03%)
Biotech Sector is Fertile Ground for Continued Rally, New Drug Developments and Latest Collaborations

PALM BEACH, Florida, October 6, 2017 /PRNewswire/ --

TRPX : 5.26 (-1.87%)
WEED.TO : 19.52 (-0.05%)
APVO : 4.18 (+5.03%)
ZYNE : 11.47 (+0.44%)
SKVI : 0.0425 (-11.46%)
MNKD : 2.81 (-5.39%)
Biotech Sector is Fertile Ground for Continued Rally, New Drug Developments and Latest Collaborations

Oppenheimer's Leah Rush Cann recently published an article on Barron's writing Biotech stocks, that still remain sharply undervalued, with an optimistic outlook that comes on the heels of the biotech sector...

TRPX : 5.26 (-1.87%)
WEED.TO : 19.52 (-0.05%)
APVO : 4.18 (+5.03%)
ZYNE : 11.47 (+0.44%)
SKVI : 0.0425 (-11.46%)
TWMJF : 15.0577 (-1.90%)
MNKD : 2.81 (-5.39%)
Aptevo Therapeutics Presents New Data on Enhanced Features of Its Next Generation ADAPTIR(TM) Bispecific Platform at the World Bispecific Summit

Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, today announced that new information on the Company's proprietary...

APVO : 4.18 (+5.03%)
Aptevo Therapeutics Extends Cash Runway $20 Million; Retains Term Loan Agreement With MidCap Financial

Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, today announced that it has amended the terms of a credit agreement...

APVO : 4.18 (+5.03%)
Aptevo Therapeutics Completes Sale of Hyperimmune Products for Up to $74.5 Million

Sharpens Focus on Innovative ADAPTIR Bispecific Antibody Platform and IXINITY Commercial Asset

APVO : 4.18 (+5.03%)
Aptevo Therapeutics Signs Agreement for Up to $74.5 Million to Sell Hyperimmune Commercial Products

Provides Significant Non-Dilutive Funding to Execute R&D Strategy

APVO : 4.18 (+5.03%)
Aptevo Therapeutics and MorphoSys End Joint Development and Commercialization Agreement for MOR209/ES414

Aptevo Regains Worldwide Rights to Novel Bispecific Prostate Cancer Immunotherapeutic MOR209/ES414

APVO : 4.18 (+5.03%)
Aptevo Therapeutics and Alligator Bioscience Commence IND-Enabling Development Activities for New Bispecific Immunotherapy Candidate ALG.APV-527

Novel Bispecific Antibody Targeting Biological Pathway Implicated in Multiple Solid Tumor Indications

APVO : 4.18 (+5.03%)
Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Rise Y/Y

Emergent's (EBS) earnings and revenues miss estimates in Q2. However, revenue increased year-over-year due to product sales and increase in contract manufacturing revenues.

APVO : 4.18 (+5.03%)
EBS : 46.80 (+1.10%)
GSK : 34.99 (-0.71%)
SNY : 43.17 (+0.19%)
Aptevo Therapeutics and Alligator Bioscience Announce Plans to Co-Develop Novel Bispecific Antibody for Tumor-Directed Immunotherapy

Strategic Partnership Will Advance Development of a Novel Bispecific

APVO : 4.18 (+5.03%)
Aptevo Therapeutics Reports First Quarter 2017 Financial Results

Expands ADAPTIR Portfolio and Announces New Bispecific Candidate; Presents Data at the

APVO : 4.18 (+5.03%)

Van Meerten Stock Picks

5 Great Mid Caps
  Today you will find that I have varied a little bit from my usual search criteria.
KBH +0.30 , IPGP +2.52 , FSLR +1.07 , NVR -6.91 , TTWO +2.17
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Mar E-mini S&Ps ( ESH18 +0.22%) this morning are up +0.16% and European stocks are down -0.34% at a 1-week low. Investors continue to pour money into U.S. equity funds at the expense of European stock funds.... Read More

Chart of the Day

Chart of the Day

Maximus (MMS) is the Barchart CHartr of the Day.  The governmental consulting firm has a Trend Spotter buy signal, a Weighted Alpha of 32.85+ and gained 31.28% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures closed the Friday session with most contracts as much as a penny lower. A private export sale of 134,503 MT of corn was sold to Costa Rica as announced by the USDA through their daily export reporting system. The Friday Commitment of Tra...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.